## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.0% below STRENGTH zone (3.0-6.0%); PEG 1.75 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($246.82)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Valley National Advisers Inc. Invests $2.04 Million in STERIS plc $STE**
- Source: MarketBeat | 20251228T130139 | Bullish | Relevance: 100%
- Valley National Advisers Inc. recently acquired a new stake of 8,265 shares in STERIS plc (NYSE:STE) during the third quarter, valued at approximately $2.04 million. This investment comes amidst significant institutional ownership of 94.69% and recent insider selling totaling $6.62 million. STERIS, a medical equipment provider, reported strong Q3 results, beating EPS and revenue estimates, and has a "Moderate Buy" consensus rating from analysts with an average price target of $273.50.

**2. Harbor Capital Advisors Inc. Has $633,000 Stock Position in STERIS plc $STE**
- Source: MarketBeat | 20251228T111054 | Somewhat-Bullish | Relevance: 100%
- Harbor Capital Advisors Inc. significantly reduced its stake in STERIS plc by 71.1% in Q3, now holding 2,559 shares valued at approximately $633,000. Despite recent insider selling totaling $6.62 million, STERIS recently surpassed quarterly EPS estimates and provided optimistic FY2026 guidance. The company, which pays a quarterly dividend of $0.63, has a market cap of $25.06 billion, a consensus analyst target of $273.50, and institutional ownership of 94.69%.

**3. STERIS's SWOT analysis: infection prevention leader's stock poised for growth**
- Source: MSN | 20251228T110906 | Bullish | Relevance: 100%
- This article analyzes STERIS plc (STE) using a SWOT framework, highlighting its strengths in the infection prevention market, opportunities for growth, potential weaknesses, and external threats. It suggests that STERIS's strong market position and strategic acquisitions make its stock an attractive investment.

**4. Copeland Capital Management LLC Reduces Stake in STERIS plc $STE**
- Source: MarketBeat | 20251230T101449 | Neutral | Relevance: 99%
- Copeland Capital Management LLC decreased its stake in STERIS plc by 4.4% in the third quarter, selling 8,400 shares and retaining 184,511 shares worth $45.66 million. Concurrently, several other institutional investors either purchased new positions or increased their holdings in STERIS. Company insiders also sold a significant amount of stock over the last three months, though analysts generally maintain a "Moderate Buy" rating for STERIS.

**5. STERIS plc $STE Position Lifted by Cwm LLC**
- Source: MarketBeat | 20251230T092531 | Bullish | Relevance: 97%
- Cwm LLC significantly increased its stake in STERIS plc (NYSE:STE) by 434.3% in Q3, now holding 32,622 shares valued at approximately $8.07 million. Institutional investors collectively own 94.69% of the company, which recently beat Q3 earnings expectations and set strong FY2026 guidance. Despite this, company insiders sold over 25,000 shares worth $6.62 million in the last quarter, reducing their ownership to 1.07%.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.75 elevated, pricing in significant growth expectations. Forward P/E 22.9x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.2B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.75 |
| Forward P/E | 22.9 |
| Current P/E | 25.0 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 3.0pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). RSI neutral at 50. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.00% (CS: 60) | Neutral |
| RSI_14 | 49.5 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.006x | Above |
| vs SMA200 | 1.064x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $255.48
- **Stop Loss:** $246.82 (3.4% risk)
- **Target:** $264.14 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 152
- **Position Value:** $38,832.96
- **Portfolio %:** 38.83%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*